endpts.com·Jul 1, 2026
Angitia Pharmaceuticals has terminated its Phase 3 trial for AGA111 in patients with degenerative disc disease, while Abivax aims to raise $800 million based on promising data for its colitis treatment.
The most valuable insight for you is Abivax's intent to raise $800 million based on promising data for colitis, signaling a significant investment opportunity in the biotech sector focused on inflammatory diseases. This development highlights the potential for substantial financial backing in biopharmaceutical companies with strong clinical data, crucial for strategic investment and partnership considerations in healthtech and biotech.